Milestone PharmaceuticalsMIST
Market Cap: $82M
About: Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Employees: 47
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
63% more call options, than puts
Call options by funds: $44K | Put options by funds: $27K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0.56% less ownership
Funds ownership: 60.51% [Q1] → 59.95% (-0.56%) [Q2]
7% less funds holding
Funds holding: 43 [Q1] → 40 (-3) [Q2]
27% less capital invested
Capital invested by funds: $57.9M [Q1] → $42.2M (-$15.7M) [Q2]
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 40 / 127 met price target | 1,523%upside $25 | Buy Reiterated | 22 Aug 2024 |
Rodman & Renshaw Brandon Folkes 50% 1-year accuracy 4 / 8 met price target | 484%upside $9 | Buy Initiated | 22 Aug 2024 |
HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 40 / 127 met price target | 1,523%upside $25 | Buy Reiterated | 1 Jul 2024 |